Charles River Laboratories International, Inc.
CRL
$291.76
$9.423.34%
NYSE
| 06/27/2026 | 03/28/2026 | 12/27/2025 | 09/27/2025 | 06/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.74% | 0.11% | -0.85% | -0.92% | -1.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.74% | 0.11% | -0.85% | -0.92% | -1.21% |
| Cost of Revenue | -0.06% | 0.46% | -1.18% | 0.38% | -0.36% |
| Gross Profit | -1.99% | -0.55% | -0.23% | -3.26% | -2.74% |
| SG&A Expenses | -1.85% | -3.06% | 0.58% | 0.59% | 4.40% |
| Depreciation & Amortization | 14.55% | 21.40% | 36.75% | 2.82% | 5.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.10% | 0.53% | 0.57% | 0.51% | 0.82% |
| Operating Income | -6.13% | -2.57% | -9.79% | -9.18% | -12.58% |
| Income Before Tax | -911.74% | -649.93% | -206.86% | -104.28% | -103.36% |
| Income Tax Expenses | 12.62% | -67.37% | -37.10% | -36.63% | -50.57% |
| Earnings from Continuing Operations | -264.20% | -684.30% | -662.11% | -118.60% | -114.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 8.51% | 29.57% | 36.83% | 48.55% |
| Net Income | -255.68% | -630.19% | -750.08% | -119.42% | -115.18% |
| EBIT | -6.13% | -2.57% | -9.79% | -9.18% | -12.58% |
| EBITDA | -8.56% | -5.35% | -9.28% | -16.78% | -10.21% |
| EPS Basic | -268.77% | -492.27% | -1,803.99% | -119.22% | -115.64% |
| Normalized Basic EPS | -23.78% | -24.19% | -8.00% | -19.14% | -17.63% |
| EPS Diluted | -265.46% | -480.62% | -2,050.69% | -119.49% | -115.90% |
| Normalized Diluted EPS | -23.66% | -24.13% | -7.87% | -18.96% | -17.38% |
| Average Basic Shares Outstanding | -3.44% | -4.02% | -3.53% | -2.68% | -1.57% |
| Average Diluted Shares Outstanding | -3.59% | -4.14% | -3.65% | -2.95% | -1.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |